NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-008-2019-0-CA-07 IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF CA National Stage 3114788 Pending
NCI E-067-2017-0-CN-05 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES CN National Stage 201880022673.3 Issued
NHGRI E-217-2018-0-US-01 Novel Vectors and Uses Thereof US 62/907,718 Abandoned
NIAID E-102-2018-0-US-03 Antibody-mediated Conditioning With Immunosuppression To Enable Allogeneic Transplantation US National Stage 16/498,572 12485186 Issued PDF
NCI E-067-2017-0-JP-07 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES JP National Stage 2019-553512 Issued
NEI E-251-2012-3-US-18 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) US DIV 16/586,656 11441184 Issued PDF
NCI E-226-2014-0-US-08 ANTI-THYROGLOBULIN T CELL RECEPTORS US DIV 16/586,310 11440956 Issued PDF
NIAID E-202-2018-0-US-02 USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTION US ORD 16/584,679 11337988 Issued PDF
NHLBI E-111-2019-0-US-01 A Method To Guide Protocol Development For Magnetic Resonance Thermometry US ORD 16/583,596 11176717 Issued PDF
NHLBI E-076-2021-0-US-01 Systems And Methods For Applying Pressure To A Bodily Organ US 62/906,399 Abandoned
NCI E-215-2018-0-AU-03 2'-HALOGENATED-4'- THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF AU National Stage 2019349424 Abandoned
NCI E-215-2018-0-JP-07 HALOGENATED 5-AZA-T-DCYD ANALOGS AND METHODS OF USE JP National Stage 2021-516619 Abandoned
NIAID E-083-2017-0-US-03 GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR
USE 		US National Stage 16/496,912 11235056 Issued PDF
NIAID E-260-2014-0-US-05 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE US DIV 16/578,748 11027007 Issued PDF
NCI E-153-2009-0-US-18 Inactivation Of Cbl-b Can Obviate The Requirement For CD28 Costimulation Of T Cells In Tumor Rejection US CON 16/579,583 10822588 Issued PDF
NCI E-215-2018-0-PCT-02 HALOGENATED 5-AZA-T-DCYD ANALOGS AND METHODS OF USE PCT PCT PCT/US2019/052410 Expired
NIAID E-220-2018-0-PCT-02 HIV-1 ENV Fusion Peptide Nanoparticle Carrier Conjugates and Their Use PCT PCT PCT/US2019/052419 Expired
NIAID E-248-2006-0-US-26 INTERGENIC SITES BETWEEN CONSERVED GENES IN THE GENOME OF MODIFIED VACCINIA ANKARA (MVA) VACCINIA VIRUS US DIV 16/579,276 Abandoned
NCI E-133-2016-0-HK-09 FLT3-Specific Chimeric Antigen Receptors and Methods Using Same HK National Stage 19129998.1 Pending
NCI E-215-2018-0-CN-05 HALOGENATED 5-AZA-T-DCYD ANALOGS AND METHODS OF USE CN National Stage 201980062607.3 Abandoned
NCI E-215-2018-0-EP-06 2'-HALOGENATED-4'- THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF EP National Stage 19782886.6 Abandoned
NCI E-215-2018-0-CA-04 2'-HALOGENATED-4'- THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF CA National Stage 3110224 Abandoned
NEI E-251-2012-3-AU-19 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) AU DIV 2019236596 Abandoned
NCI E-131-2018-0-CN-07 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD123 IMMUNOTHERAPY CN National Stage 201980076357.9 Issued
NHLBI E-186-2014-1-JP-09 SUPERAGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 JP DIV 2019-172064 Issued
NCI E-116-2017-0-JP-09 Human Antibodies Against CD33 JP National Stage 2019-552109 Issued
NCI E-131-2018-0-US-03 Fully Human Antibody Targeting Human CD123 For Cancer Threpeutics Development US ORD 16/578,063 10844128 Issued PDF
NCI E-131-2018-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD123 IMMUNOTHERAPY PCT PCT PCT/US2019/052226 Expired
NCI E-010-2019-0-PCT-02 Compositions And Methods For Modulation Of LMNA Expression PCT PCT PCT/US2019/052223 Expired
NCI E-131-2018-0-AU-06 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD123 IMMUNOTHERAPY AU National Stage 2019343184 Pending
NCI E-067-2017-0-US-08 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES US National Stage 16/495,508 11898207 Issued PDF
NCI E-168-2018-0-US-01 METHODS OF ISOLATING T CELL POPULATIONS US 62/902,184 Abandoned
CC E-076-2017-0-US-03 METHOD AND SYSTEM OF BUILDING HOSPITAL-SCALE CHEST X-RAY DATABASE FOR ENTITY EXTRACTION AND WEAKLY-SUPERVISED CLASSIFICATION AND LOCALIZATION OF COMMON THORAX DISEASES US National Stage 16/495,012 11583239 Issued PDF
NCI E-205-2018-0-PCT-02 Bicistronic Chimeric Antigen Receptor Constructs Targeting CD19 And CD20 PCT PCT PCT/US2019/051517 Expired
NCI E-176-2022-0-US-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease US 62/901,638 Expired
NCATS E-203-2012-0-US-12 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 US CON 16/570,470 11129835 Issued PDF
NCI E-182-2019-0-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER US 62/900,240 Abandoned
NEI E-227-2018-0-US-01 Metformin For The Treatment Of Age-related Retinal Degeneration US 62/899,899 Abandoned
NCI E-148-2011-0-HK-37 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer HK EP 19129515.3 Issued
NHGRI E-122-2017-0-US-01 CANCER DETECTION AND CLASSIFICATION US 62/898,670 Abandoned
NCI E-016-2019-0-EP-04 Methods Of Decreasing Influenza-induced Lethality Using Gastrin Releasing Peptide (GRP) Or Gastrin Releasing Peptide Receptor (GRPR) Antagonists EP National Stage 19859381.6 Issued
NIAAA E-140-2014-0-AU-11 PYRAZOLE DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MEDIATORS AU DIV 2019227889 Issued
NCI E-016-2019-0-PCT-02 Methods Of Decreasing Influenza-induced Lethality Using Gastrin Releasing Peptide (GRP) Or Gastrin Releasing Peptide Receptor (GRPR) Antagonists PCT PCT PCT/US2019/050312 Expired
NCI E-030-2022-0-US-01 Anti-Viral Compositions And Methods Of Making And Using US 62/898,383 Abandoned
NIDA E-053-2016-2-PCT-02 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF PCT PCT PCT/US2019/050165 Expired
NIDA E-053-2016-2-EP-05 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF EP National Stage 19773300.9 Pending
NIDA E-053-2016-2-CA-04 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF CA National Stage 3111785 Pending
NHLBI E-222-2022-7-US-01 Catheters and Manipulators with Articulable Ends US CIP 16/563,925 12133962 Issued PDF
NIAID E-150-2022-0-AU-03 Compositions And Methods For Preventing And/or Treating Filarial Disease AU National Stage 2019336212 Issued
NCI E-266-2011-0-HK-35 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage HK CN 19129278.8 Issued